Sartorius Aktiengesellschaft Stock News

Laboratory Filtration Market: Overview The laboratory filtration market has been estimated to grow at a significant speed during the forecast period. This market growth has been on the back of increased spending on R & D activities in the pharmaceutical and

Sterility Testing Market The sterility testing market was valued at USD 810 million in 2017 and is projected to witness CAGR growth of 7.4% during the forecast period 2019-2026 to surpass the value of USD 1,617 million by 2026. Sterility testing is

Sartorius Aktiengesellschaft (ETR:SRT) shares fell 1.4% during mid-day trading on Wednesday . The company traded as low as 500.00 ($588.24) and last traded at 504.00 ($592.94). 4,413 shares were traded during mid-day trading, The stock had previously closed at 511.00 ($601.18). The stock has a 50-day simple moving average of 590.78 and a 200-day simple []

Sartorius Aktiengesellschaft (OTCMKTS:SUVPF) was down 4% on Thursday . The stock traded as low as $619.18 and last traded at $619.18. Approximately 232 shares were traded during trading, a decline of 46% from the average daily volume of 431 shares. The stock had previously closed at $644.72. Separately, Deutsche Bank Aktiengesellschaft restated a buy rating []

SARTORIUS (SARTF) possesses solid growth attributes, which could help it handily outperform the market.

Coave Therapeutics appoints Chief Medical Officer and Chief Operating Officer Submitted 15/11/2021 - 9:15am Coave Therapeutics (Coave), a clinical-stage biotechnology company backed by international life science and strategic investors Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, Sham Innovation Santé/Turenne, has strengthened its leadership team with the appointments of Thomas Blaettler MD, as Chief Medical Officer, and Patricia Françon PhD, to the newly created position of Chief Operating Officer. I am very pleased to welcome Thomas and Patricia to the leadership team at Coave. Their collective accomplishments and deep domain expertise in neuroscience, cell and gene therapy, in addition to their extensive clinical drug development and project management experience will be invaluable as we progress our lead candidate through clinical development and advance our pipeline of novel gene therapies into clinical development targeting rare Ocular and CNS diseases, says Rodolphe Clerval, CEO.

SARTORIUS (SARTF) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Sartorius Aktiengesellschaft (SARTF) CEO Joachim Kreuzburg on Q3 2021 Results - Earnings Call Transcript

SARTORIUS (SARTF) delivered earnings and revenue surprises of 7.59% and 5.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SARTORIUS AG (SARTF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increa

SARTORIUS AG (SARTF) is well positioned to outperform the market, as it exhibits above-average growth in financials.

SARTORIUS AG (SARTF) possesses solid growth attributes, which could help it handily outperform the market.

SARTORIUS AG (SARTF) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.